Laurent Chardonnet's Insider Trades & SAST Disclosures
Laurent Chardonnet's most recent trade in Prelude Therapeutics Inc was a trade of 150,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Laurent Chardonnet.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 23 May 2023 | 5,000 | 42,165 | - | 5.5 | 27,500 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.76 per share. | 08 Dec 2022 | 10,000 | 35,873 | - | 4.8 | 47,600 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.23 per share. | 01 Jun 2022 | 10,000 | 24,500 | - | 4.2 | 42,300 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 7.51 per share. | 21 Mar 2022 | 6,500 | 14,500 | - | 7.5 | 48,815 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Axcella Health Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Axcella Health Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 60,000 | 60,000 | - | - | Restricted Stock Units | |
| Axcella Health Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Axcella Health Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.60 per share. | 09 Feb 2021 | 2,601 | 6,266 (0%) | 0% | 3.6 | 9,364 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges